• Citer

Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trial.

par Collet, L;Noël, J-C;Catteau, Xavier ;Ardin, Maude;Berthet, Justine;Ghamry-Barrin, Sarah;Treilleux, I;Bengrine Lefevre, Leïla;Martinez, M;Rothé, Françoise ;Sotiriou, Christos ;Caux, C;Dubois, B;Ray-Coquard, Isabelle;Le Saux, Olivia
Référence ESMO Open, 10, 6, page (105104)
Publication Publié, 2025-06-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trial.
Auteur:	Collet, L; Noël, J-C; Catteau, Xavier; Ardin, Maude; Berthet, Justine; Ghamry-Barrin, Sarah; Treilleux, I; Bengrine Lefevre, Leïla; Martinez, M; Rothé, Françoise; Sotiriou, Christos; Caux, C; Dubois, B; Ray-Coquard, Isabelle; Le Saux, Olivia
Informations sur la publication:	ESMO Open, 10, 6, page (105104)
Statut de publication:	Publié, 2025-06-01
Sujet CREF:	Sciences bio-médicales et agricoles
Mots-clés:	high-grade serous ovarian cancer
	immunotherapy
	platinum-based chemotherapy
	tumor microenvironment
	tumor–stroma proportion
MeSH keywords:	Humans
	Female
	Ovarian Neoplasms -- pathology -- drug therapy -- mortality
	Prognosis
	Middle Aged
	Aged
	Biomarkers, Tumor
	Antibodies, Monoclonal, Humanized -- therapeutic use
	Immunotherapy -- methods
	Tumor Microenvironment
	Adult
	Stromal Cells -- pathology
	Immune Checkpoint Inhibitors -- therapeutic use
Langue:	Anglais
Identificateurs:	urn:issn:2059-7029
	info:doi/10.1016/j.esmoop.2025.105104
	info:pii/S2059-7029(25)00973-1
	info:pmid/40472658
	PMC12172955